Back to search
FDAFDA · Food and drugs·Recall number D-0515-2024

Moxifloxacin 0.8 mg/0.8 mL Preservative-Free 0.8mL Single-Use vials for Intraocular Injection, Rx only, Imprimis NJOF, LLC. 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852, NDC 71384-509-08

Published June 5, 2024 · Recall initiated: May 14, 2024

Summary

FDA records drug Class II recall D-0515-2024, published June 5, 2024 and initiated May 14, 2024. Recalling firm: Imprimis NJOF, LLC; Status: Ongoing; Reported quantity: 18,980 vials; Lot: Lot #: 23OCT013, Exp. Date 10/10/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
Nationwide within the United States
Lot
Lot #: 23OCT013, Exp. Date 10/10/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Moxifloxacin 0.8 mg/0.8 mL Preservative-Free 0.8mL Single-Use vials for Intraocular Injection, Rx only, Imprimis NJOF, LLC. 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852, NDC 71384-509-08 recalled?

Yes. FDA published recall D-0515-2024 on June 5, 2024. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated